Weight Loss on Ozempic: Clinical Data & Genetic Factors

Last reviewed: May 19, 2026

Last updated: May 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Clinical trials show average weight loss on Ozempic (semaglutide) ranges from 5% to 15% of baseline body weight over 68 weeks, depending on dose escalation and individual response. However, this average masks significant variability: some patients lose 3-5%, others exceed 20%.

Understanding your personal metabolic context—including biomarker status, genetic predispositions in GLP-1 receptor signaling, and baseline insulin resistance—can help set realistic expectations and support more targeted conversations with your provider about whether GLP-1 therapy aligns with your health goals.

Clinical Trial Data: What the Research Actually Shows

The pivotal SUSTAIN trials (which tested semaglutide in type 2 diabetes) demonstrated average weight loss of approximately 3-4 kg with the 0.5 mg dose and 6-7 kg with the 1 mg dose over 30 weeks. Patients continuing to higher maintenance doses achieved greater cumulative loss.

The STEP trials, which studied semaglutide in non-diabetic overweight or obese individuals, reported mean weight loss of 9.2-12.4% of baseline body weight at 68 weeks. However, approximately 35% of placebo-treated patients also lost significant weight, highlighting the importance of diet, exercise, and behavioral factors independent of medication.

Individual Response Variability and Metabolic Factors

Weight loss response varies dramatically between individuals due to differences in baseline metabolic rate, insulin sensitivity, gut hormone signaling, adherence, and dietary habits. Two patients on identical doses may experience 5-fold differences in weight loss over the same timeframe.

Key metabolic markers that providers may assess before and during treatment include fasting glucose, insulin levels, HOMA-IR (insulin resistance index), and lipid profiles. These biomarkers can provide context for expected response patterns and help identify patients who may require dose adjustments or additional interventions.

Biomarker / Factor	Relevance to Weight Loss Response
Baseline BMI	Higher baseline BMI correlates with greater absolute weight loss but similar percentage loss
Fasting Insulin / HOMA-IR	Higher baseline insulin resistance may predict greater initial response to GLP-1 therapy
HbA1c and Fasting Glucose	Baseline glycemic control influences metabolic flexibility and appetite regulation during treatment
Lipid Profile (TG, HDL)	May reflect metabolic syndrome severity and predict concurrent cardiovascular benefit from weight loss
Gastric Emptying Rate	Individual variation affects satiety signaling and tolerance to dose escalation
GLP-1R Genetic Variants	Specific variants (e.g., rs6923761) may relate to endogenous GLP-1 sensitivity and medication response

Timeline and Dose-Response Expectations

Weight loss typically begins within 2-4 weeks of starting GLP-1 therapy, with the most rapid loss occurring during the first 12-16 weeks. Continued gradual loss often continues through 52 weeks, after which weight loss may plateau or stabilize if lifestyle factors remain consistent.

Dose escalation protocols (starting 0.25 mg weekly, increasing to 0.5-1 mg over 4 weeks) allow providers to optimize tolerability while assessing individual response. Some patients reach plateau weight at lower doses, while others benefit from continuing to maximum maintenance doses for sustained loss.

Who Should Have Realistic Expectations and Safety Considerations

Patients with type 2 diabetes, severe obesity (BMI >30), or metabolic syndrome typically show more consistent weight loss responses than those with mild overweight and normal glucose tolerance. Conversely, patients with eating disorders, binge eating patterns, or severe gastroparesis may not be suitable candidates or may require additional monitoring.

Sustained weight loss requires ongoing medication adherence, dietary consistency, and physical activity. Discontinuation often leads to weight regain. Providers should discuss realistic long-term expectations, potential side effects (nausea, vomiting, pancreatitis risk in specific populations), and the importance of regular metabolic monitoring during treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key genetic variants in GLP-1 receptor (GLP1R rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) pathways—regions linked to appetite regulation, metabolic rate, and satiety signaling. These genetic predispositions may help provide context for why certain individuals show stronger or weaker responses to GLP-1 medications.

The test reveals your genetic predispositions within peptide hormone pathways, not exact medication response. A variant associated with higher baseline GLP-1 sensitivity, for example, might suggest you could achieve meaningful weight loss at lower doses, while another pattern might indicate need for higher maintenance dosing or concurrent lifestyle interventions. This information should be interpreted with a qualified healthcare provider.

Combining genetic insights with clinical biomarkers (baseline insulin, lipids, glucose tolerance) and metabolic history can support a more personalized conversation between you and your provider about realistic weight loss targets, optimal dosing strategy, and timeline expectations before starting compounded semaglutide or other GLP-1 therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.